39
Pharma & HealthcareAvoid
Nippon India Pharma
Nippon India · Direct–Growth · rank #13 of 19 by Smart Score
Data updated
Trailing returns
1 Year
14.1%
+13.3% vs index
3 Years
17.8%
+6.3% vs index
5 Years
15.2%
+5.1% vs index
Since launch
17.6%
Year-by-year performance
2021
+25.1%-5.5% vs index
2022
-9.1%-12.9% vs index
2023
+40.4%+13.8% vs index
2024
+35.3%+19.6% vs index
2025
-2.5%-10.1% vs index
2026
+15.9%+15.0% vs index
Why this score
Nippon India Pharma scores 39/100 — #13 of 19 Pharma & Healthcare fund (Avoid). It stands out for volatility and fund size — beating 91% of peers on volatility. The main drag is its 3y return (better than only 4% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
3Y return17.80% · 4th percentile in category
5Y return15.22% · 15th percentile in category
Volatility13.13 · 91st percentile in category
Fund size9087.27 Cr · 97th percentile in category
Sharpe ratio0.85 · 25th percentile in category
1Y return14.05% · 15th percentile in category
Top holdings
1.Sun Pharmaceutical Industries Ltd11.55%
2.Divi's Laboratories Ltd6.73%
3.Cipla Ltd6.21%
4.Lupin Ltd6.16%
5.Dr. Reddy's Laboratories Ltd6.13%
37 disclosed equity positions · portfolio as of Oct 2026 · weights are % of total corpus.